of Juno Therapeutics jump after FDA removes clinical hold on cancer drug
Send a link to a friend
[July 13, 2016]
(Reuters) - Juno Therapeutics Inc
said U.S. health regulators have removed a clinical hold on its cancer
drug trial that was put in place last week following the death of three
patients, sending its shares up about 28 percent in extended trading.
Last week, the U.S. Food and Drug Administration halted the
mid-stage trial of the company's genetically engineered cancer drug
after three leukemia patients died from side effects.
Juno said the deaths occurred after the chemotherapy agent
fludarabine was added to the trial program. Under the new protocol,
the trial will continue enrollment using the original drug regimen,
The drug, JCAR015, is an experimental therapy requiring a
complicated process of extracting immune system T cells from an
individual patient, altering their DNA to sharpen their ability to
spot and kill cancer cells, and infusing them back into the same
(Reporting by Amrutha Penumudi in Bengaluru; Editing by Anil D'Silva)
[© 2016 Thomson Reuters. All rights
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.